{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T22:29:34Z","timestamp":1775341774933,"version":"3.50.1"},"reference-count":112,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2010,4,9]],"date-time":"2010-04-09T00:00:00Z","timestamp":1270771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cutaneous malignant melanoma is the most lethal form of skin cancer and an increasingly common disease worldwide. It remains one of the most treatment-refractory malignancies. The current treatment options for patients with metastatic melanoma are limited and in most cases non-curative. This review focuses on conventional chemotherapeutic drugs for melanoma treatment, by a single or combinational agent approach, but also summarizes some potential novel phytoagents discovered from dietary vegetables or traditional herbal medicines as alternative options or future medicine for melanoma prevention. We explore the mode of actions of these natural phytoagents against metastatic melanoma.<\/jats:p>","DOI":"10.3390\/cancers2020397","type":"journal-article","created":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T11:23:10Z","timestamp":1271071390000},"page":"397-419","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Current Research and Development of Chemotherapeutic Agents for Melanoma"],"prefix":"10.3390","volume":"2","author":[{"given":"Kyaw Minn","family":"Hsan","sequence":"first","affiliation":[{"name":"Institute of Plant Biology, National Taiwan University, Taipei 106, Taiwan"},{"name":"Agricultural Biotechnology Research Center, Academia Sinica, Taipei 115, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Chieh","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Plant Biology, National Taiwan University, Taipei 106, Taiwan"},{"name":"Agricultural Biotechnology Research Center, Academia Sinica, Taipei 115, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lie-Fen","family":"Shyur","sequence":"additional","affiliation":[{"name":"Agricultural Biotechnology Research Center, Academia Sinica, Taipei 115, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2010,4,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/canjclin.50.1.7","article-title":"Cancer statistics, 2000","volume":"50","author":"Greenlee","year":"2000","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1011-1344(01)00198-1","article-title":"The epidemiology of UV induced skin cancer","volume":"63","author":"Armstrong","year":"2001","journal-title":"J. Photochem. Photobio. B, Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/carcin\/bgp207","article-title":"DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Mocellin","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Mechanisms of disease melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1155\/S1110724301000031","article-title":"A model for UV-induction of skin cancer","volume":"1","author":"Ouhtit","year":"2001","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CEJ.0b013e328313631a","article-title":"A prospective study of gout and cancer","volume":"18","author":"Boffetta","year":"2009","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2308s","DOI":"10.1158\/1078-0432.CCR-05-2504","article-title":"Pathology of melanoma","volume":"12","author":"Elder","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_9","first-page":"8058","article-title":"Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene","volume":"14","author":"Yasumoto","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature03664","article-title":"Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma","volume":"436","author":"Garraway","year":"2005","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00008390-199602000-00004","article-title":"c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi","volume":"6","author":"Ohashi","year":"1996","journal-title":"Melanoma Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/jid.2008.374","article-title":"Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma","volume":"129","author":"Greene","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMra041245","article-title":"Management of cutaneous melanoma","volume":"351","author":"Tsao","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.2007.14.3156","article-title":"Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients","volume":"26","author":"Gimotty","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0959-8049(94)90137-6","article-title":"A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma","volume":"30A","author":"Philip","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"ref_18","first-page":"1989","article-title":"DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine","volume":"63","author":"Hill","year":"1979","journal-title":"Cancer Treat. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1053\/sonc.2002.35238","article-title":"Metastatic melanoma: chemotherapy","volume":"29","author":"Bajetta","year":"2002","journal-title":"Semin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.1995.13.4.910","article-title":"Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma","volume":"13","author":"Bleehen","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1471-2407-5-147","article-title":"Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives","volume":"5","author":"Durando","year":"2005","journal-title":"BMC Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3109\/07357909409038234","article-title":"Fotemustine in the treatment of brain primary tumors and metastases","volume":"12","author":"Khayat","year":"1994","journal-title":"Cancer Invest."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/1097-0142(19901101)66:9<1873::AID-CNCR2820660904>3.0.CO;2-5","article-title":"Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases","volume":"66","author":"Jacquillat","year":"1990","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00001622-199703000-00016","article-title":"The treatment of metastatic melanoma with chemotherapy and biologics","volume":"9","author":"Atkins","year":"1997","journal-title":"Curr. Opin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1200\/JCO.1987.5.4.574","article-title":"WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma","volume":"5","author":"Glover","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"ref_27","first-page":"171","article-title":"Phase II trial of carboplatin in advanced malignant melanoma","volume":"71","author":"Evans","year":"1987","journal-title":"Cancer Treat. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00000421-199502000-00012","article-title":"A phase II trial of zeniplatin in metastatic melanoma","volume":"18","author":"Olver","year":"1995","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/1568009033481967","article-title":"Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action","volume":"3","author":"Abal","year":"2003","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00008390-200402000-00010","article-title":"Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma","volume":"14","author":"Bedikian","year":"2004","journal-title":"Melanoma Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.1984.2.4.316","article-title":"Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study","volume":"2","author":"Quagliana","year":"1984","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"vi35","DOI":"10.1093\/annonc\/mdp254","article-title":"Small molecules and targeted therapies in distant metastatic disease","volume":"20","author":"Hersey","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_33","first-page":"475","article-title":"Targeted therapy in melanoma","volume":"3","author":"Tawbi","year":"2009","journal-title":"Biologics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/14796694.3.3.263","article-title":"Oblimersen in the treatment of metastatic melanoma","volume":"3","author":"Tarhini","year":"2007","journal-title":"Future Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":"Oblimersen Melanoma Study Group. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group","volume":"24","author":"Bedikian","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1517\/14728222.12.2.209","article-title":"Mammalian target of rapamycin as a therapeutic target in oncology","volume":"12","author":"Abraham","year":"2008","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.transproceed.2009.06.040","article-title":"Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation","volume":"41","author":"Gonzalez","year":"2009","journal-title":"Transplant Proc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy","volume":"445","author":"Wellbrock","year":"2007","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1158\/1078-0432.CCR-05-2505","article-title":"Chemotherapy and targeted therapy combinations in advanced melanoma","volume":"12","author":"Flaherty","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a phase III, randomized, placeobo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma","volume":"27","author":"Hauschild","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.2007.14.8288","article-title":"Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 study group","volume":"26","author":"McDermott","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.coph.2008.06.014","article-title":"Therapeutic strategies for inhibiting oncogenic BRAF signaling","volume":"8","author":"Halilovic","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"abstract 9000","DOI":"10.1200\/jco.2009.27.15_suppl.9000","article-title":"Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer","volume":"27","author":"Flaherty","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_45","first-page":"17","article-title":"Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoisotochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial","volume":"22","author":"Fiorentini","year":"2003","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6602529","article-title":"Lack of clinical efficacy of imatinib in metastatic melanoma","volume":"98","author":"Ugurel","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/cncr.21834","article-title":"Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy","volume":"106","author":"Wyman","year":"2006","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1158\/1078-0432.CCR-08-1002","article-title":"Phase II trial of 17-allylamino-17demethoxygeldanamycin in patients with metastatic melanoma","volume":"14","author":"Solit","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23987","article-title":"Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A","volume":"115","author":"Perez","year":"2009","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000138351","article-title":"Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma","volume":"74","author":"Viteri","year":"2008","journal-title":"Oncology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00000421-198810000-00016","article-title":"Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study","volume":"11","author":"Fletcher","year":"1988","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000219435","article-title":"Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma","volume":"55","author":"Ott","year":"2009","journal-title":"Chemotherapy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/CMR.0b013e3283350578","article-title":"Temozolomide and cisplatin combination in na\u00efve patients with metastatic cutaneous melanoma: results of a phase II multicenter trial","volume":"20","author":"Sassolas","year":"2010","journal-title":"Melanoma Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00280-008-0861-0","article-title":"Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma","volume":"64","author":"Kim","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/COC.0b013e3181942a1f","article-title":"Phase I\/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma","volume":"32","author":"Papadopoulos","year":"2009","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","article-title":"Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2 and interferon alfa-2b with cisplatin, vinblastine and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the eastern cooperative oncology group","volume":"26","author":"Atkins","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/CMR.0b013e328328f7ec","article-title":"Multicentre, open, noncomparative phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients","volume":"19","author":"Ridolfi","year":"2009","journal-title":"Melanoma Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1248\/bpb.33.117","article-title":"Preventive effect of green tea catechins on experimental tumor metastasis in senescence-accelerated mice","volume":"33","author":"Shimizu","year":"2010","journal-title":"Biol. Pharm. Bull."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/ecam\/nem140","article-title":"Differential growth suppression of human melanoma cells by tea (Camellia sinensis) epicatechins (ECG, EGC and EGCG)","volume":"6","author":"Ravindranath","year":"2009","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ijc.20785","article-title":"Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma","volume":"114","author":"Nihal","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.4161\/cc.8.13.8862","article-title":"(-)Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma","volume":"8","author":"Nihal","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jcb.1261","article-title":"Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice","volume":"83","author":"Liu","year":"2001","journal-title":"J. Cell. Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd2060","article-title":"Therapeutic potential of resveratrol: the in vivo evidence","volume":"5","author":"Baur","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.275.5297.218","article-title":"Cancer chemopreventive activity of resveratrol, a natural product derived from grapes","volume":"275","author":"Jang","year":"1997","journal-title":"Science"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbrc.2005.06.073","article-title":"Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53","volume":"334","author":"Hsieh","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/01.cmr.0000130007.54508.b2","article-title":"In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide","volume":"14","author":"Fuggetta","year":"2004","journal-title":"Melanoma Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00394-004-0471-5","article-title":"The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells","volume":"43","author":"Larrosa","year":"2004","journal-title":"Eur. J. Nutr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/carcin\/15.10.2363","article-title":"Effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate- and ultraviolet B light-induced expression of c-Jun and c-Fos in JB6 cells and in mouse epidermis","volume":"15","author":"Lu","year":"1994","journal-title":"Carcinogenesis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0304-3835(95)03887-3","article-title":"Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds","volume":"95","author":"Menon","year":"1995","journal-title":"Cancer Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CMR.0b013e3282ed3d0e","article-title":"Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells","volume":"17","author":"Wall","year":"2007","journal-title":"Melanoma Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/mol.109.059105","article-title":"An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells","volume":"76","author":"Wang","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0304-3835(99)00098-1","article-title":"Anti-metastatic activity of curcumin and catechin","volume":"141","author":"Menon","year":"1999","journal-title":"Cancer Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/1097-0215(20000815)87:4<595::AID-IJC21>3.0.CO;2-5","article-title":"Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential","volume":"87","author":"Caltagirone","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0006-2952(01)00583-4","article-title":"Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1","volume":"61","author":"Casagrande","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-1-4757-4820-8_11","article-title":"Anticancer therapeutic potential of soy isoflavone, genistein","volume":"546","author":"Ravindranath","year":"2004","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jnutbio.2005.05.011","article-title":"Genistin inhibits UV light-induced plasmid DNA damage and cell growth in human melanoma cells","volume":"17","author":"Russo","year":"2006","journal-title":"J. Nutr. Biochem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1034\/j.1600-0749.2003.00068.x","article-title":"Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells","volume":"16","author":"Tamura","year":"2003","journal-title":"Pigment Cell Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/08923970701692676","article-title":"Effect of Punarnavine, an alkaloid from Boerhaavia diffusa, on cell-mediated immune responses and TIMP-1 in B16F-10 metastatic melanoma-bearing mice","volume":"29","author":"Manu","year":"2007","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.imbio.2008.10.002","article-title":"Anti-metastatic potential of Punarnavine, an alkaloid from Boerhaavia diffusa Linn","volume":"214","author":"Manu","year":"2009","journal-title":"Immunobiology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0031-9422(97)00345-2","article-title":"Carbazole alkaloids from Murraya koenigii","volume":"46","author":"Chakrabarty","year":"1997","journal-title":"Phytochemistry"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0031-9422(99)00575-0","article-title":"Bioactive alkaloids from Brunsvigia radulosa","volume":"53","author":"Campbell","year":"2000","journal-title":"Phytochemistry"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1271\/bbb.80279","article-title":"Depigmenting mechanisms of all-trans retinoic acid and retinol on B16 melanoma cells","volume":"72","author":"Sato","year":"2008","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00280-008-0763-1","article-title":"Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma","volume":"63","author":"Liu","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1207\/s15327914nc4701_10","article-title":"Mechanism of activation of caspase cascade during beta-carotene-induced apoptosis in human tumor cells","volume":"47","author":"Palozza","year":"2003","journal-title":"Nutr. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.lfs.2007.09.018","article-title":"Lycopene inhibits PDGF-BB-induced signaling and migration in human dermal fibroblasts through interaction with PDGF-BB","volume":"81","author":"Chiang","year":"2007","journal-title":"Life Sci."},{"key":"ref_86","first-page":"41","article-title":"A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study","volume":"5","author":"Sondak","year":"1999","journal-title":"Cancer J. Sci. Am."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/CAD.0b013e3282f2c0bc","article-title":"Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma","volume":"19","author":"Recchia","year":"2008","journal-title":"Anticancer Drugs."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/1055-9965.1042.13.6","article-title":"Diet and melanoma in a case-control study","volume":"13","author":"Millen","year":"2004","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/archdermatol.2009.176","article-title":"Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study","volume":"145","author":"Asgari","year":"2009","journal-title":"Arch. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0006-2952(02)01483-1","article-title":"Effects of glycolipids from spinach on mammalian DNA polymerases","volume":"65","author":"Murakami","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2174\/092986707780362952","article-title":"Inhibitory effect on replicative DNA polymerases, human cancer cell proliferation, and in vivo anti-tumor activity by glycolipids from spinach","volume":"14","author":"Maeda","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1158\/0008-5472.CAN-07-0158","article-title":"A galactolipid possesses novel cancer chemopreventive effects by suppressing inflammatory mediators and mouse B16 melanoma","volume":"67","author":"Hou","year":"2007","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2146\/ajhp080411","article-title":"Therapeutic potential of n-3 polyunsaturated fatty acids in disease","volume":"66","author":"Fetterman","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cdp.2006.04.008","article-title":"The potential of omega-3 fatty acids in the prevention of non-melanoma skin cancer","volume":"30","author":"Black","year":"2006","journal-title":"Cancer Detect Prev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1017\/S0007114508043791","article-title":"An enhanced apoptosis and a reduced angiogenesis are associated with the inhibition of lung colonisation in animals fed an n-3 polyunsaturated fatty acid-rich diet injected with a highly metastatic murine melanoma line","volume":"101","author":"Mannini","year":"2009","journal-title":"Br. J. Nutr."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"12499","DOI":"10.1073\/pnas.0605394103","article-title":"Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6\/omega-3 essential fatty acids","volume":"103","author":"Xia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.phytochem.2009.06.007","article-title":"Methyl jasmonate: a plant stress hormone as an anti-cancer drug","volume":"70","author":"Cohen","year":"2009","journal-title":"Phytochemistry"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2006.03.001","article-title":"Jasmonates in cancer therapy","volume":"245","author":"Flescher","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/sj.bjp.0707146","article-title":"Effects of natural and novel synthetic jasmonates in experimental metastatic melanoma","volume":"150","author":"Reischer","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/sj.leu.2402419","article-title":"Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells","volume":"16","author":"Fingrut","year":"2002","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.lfs.2005.12.038","article-title":"Antimetastatic activity of Sulforaphane","volume":"78","author":"Thejass","year":"2006","journal-title":"Life Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/08923970701511728","article-title":"Modulation of cell-mediated immune response in B16F-10 melanoma-induced metastatic tumor-bearing C57BL\/6 mice by sulforaphane","volume":"29","author":"Thejass","year":"2007","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/01635580802567166","article-title":"Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells","volume":"61","author":"Chang","year":"2009","journal-title":"Nutr. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jcp.21391","article-title":"Vitamin C suppresses proliferation of the human melanoma cell SK-MEL-2 through the inhibition of cyclooxygenase-2 (COX-2) expression and the modulation of insulin-like growth factor II (IGF-II) production","volume":"216","author":"Lee","year":"2008","journal-title":"J. Cell Physiol."},{"key":"ref_105","first-page":"315","article-title":"Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells","volume":"23","author":"Fei","year":"2002","journal-title":"Acta. Pharmacol. Sin."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-4632.2009.03946.x","article-title":"Gambogic acid induces apoptosis by regulating the expression of Bax and Bcl-2 and enhancing caspase-3 activity in human malignant melanoma A375 cells","volume":"48","author":"Xu","year":"2009","journal-title":"Int. J. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-4632.2008.03627.x","article-title":"Matrine inhibits invasiveness and metastasis of human malignant melanoma cell line A375 in vitro","volume":"47","author":"Liu","year":"2008","journal-title":"Int. J. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.canlet.2005.08.024","article-title":"Berberine anti-proliferative activity in vitro and induction of apoptosis\/necrosis of the U937 and B16 cells","volume":"239","year":"2006","journal-title":"Cancer Lett."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.bbrc.2009.06.042","article-title":"Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by Vascular Endothelial Growth Factor","volume":"386","author":"Chen","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2006-06-032250","article-title":"Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo","volume":"109","author":"Zhou","year":"2007","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1254\/jphs.FPJ06016X","article-title":"Oridonin-induced A431 cell apoptosis partially through blockage of the Ras\/Raf\/ERK signal pathway","volume":"103","author":"Li","year":"2007","journal-title":"J. Pharmacol. Sci."},{"key":"ref_112","first-page":"65","article-title":"Triptolide inhibits the growth and metastasis of solid tumors","volume":"2","author":"Yang","year":"2003","journal-title":"Mol. Cancer Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/2\/2\/397\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:02:05Z","timestamp":1760220125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/2\/2\/397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,9]]},"references-count":112,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2010,6]]}},"alternative-id":["cancers2020397"],"URL":"https:\/\/doi.org\/10.3390\/cancers2020397","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,9]]}}}